|
Chernyavskaya O.A., Ioannidi E.A., Ogulchanskaya E.G.
A comparative analysis of changes in HIV/AIDS awareness among young people living in the Volgograd Region over the past decade
|
№6 / 2014
|
|
Sarmometov E.V., Sergevnin V.I., Shmagin D.V., Mikova O.E.
Primary HIV infection in the development of HIV/tuberculosis co-infection
|
№5 / 2014
|
|
Kozyrina N.V., Narsia R.S., Yurin O.G.
Abacavir and lamivudine as a nucleoside base of antiretroviral therapy
|
№5 / 2014
|
|
Moskvicheva M.G., Radzikhovskaya M.V., Kuzyukin N.N.
The specific features of HIV infection epidemic in the Chelyabinsk Region
|
№5 / 2014
|
|
Moskvicheva M.G., Radzikhovskaya M.V.
Experience with the HIV protease inhibitor fosamprenavir in first-line antiretroviral therapy regimens in the Chelyabinsk Region
|
№3 / 2014
|
|
Semenova N.Yu., Chebotareva T.V., Bogdanova L.I., Demidov V.I.
The clinical and morphological features of HIV-associated tuberculosis
|
№3 / 2014
|
|
Kanestri V.G.
Contribution of a fixed-dose abacavir/lamivudine combination to improving treatment compliance in HIV-infected patients
|
№6 / 2013
|
|
Gushchina Yu.Sh., Kubaeva M. B.
Prospects for the long-term efficaсay of fosamprenavir (telzir) used as part of antiretroviral therapy in hiv-infected patients
|
№6 / 2013
|
|
Pyadushkina E.A., Goryaynov S.V., Omelyanovsky V.V., Avxentyeva M.V., Rebrova O.Yu.
Clinicoeconomic analysis of the use of maraviroc versus other reserve drugs in patients who have experienced antiretroviral therapy for HIV infection
|
№5 / 2013
|
|
Volkova S.B., Podymova A.S.
Experience with the HIV protease inhibitor fosamprenavir in russian practice
|
№4 / 2013
|
|
Isaeva G.N., Kovelenov A.Yu.
The efficacy and safety of a second-generation nonnucleotide reverse transcriptase inhibitor as part of combination antiretroviral therapy in HIV-infected patients
|
№4 / 2013
|
|
Sundukov A.V., Gafurov Yu.T., Evsyukov O. A.
Clinical and laboratory features of abnormalities in the cervix uteri, external genitals, and vagina in HIV-infected patients
|
№4 / 2013
|
Русский
